nach oben

Erschienen in:

29.05.2015 | Original Contribution

Mid-regional-pro-adrenomedullin plasma levels are increased in obese adolescents

verfasst von: Silvia Del Ry, Manuela Cabiati, Vanessa Bianchi, Laura Caponi, Pietro Di Cecco, Benedetta Marchi, Emioli Randazzo, Chiara Caselli, Tommaso Prescimone, Aldo Clerico, Giovanni Federico

Erschienen in: European Journal of Nutrition | Ausgabe 3/2016

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Recently, adrenomedullin (ADM) was defined as a new member of the adipokine family. ADM secreted by adipocytes, through its vasodilator and antioxidant actions, might be protective against metabolic syndrome-associated cardiovascular complications. The aim of the study was to assess plasma mid-regional (MR)-proADM levels in obese adolescents compared to normal-weight subjects and its relation with BMI, body composition and metabolic indices.

Methods

Plasma MR-proADM was measured in 32 healthy adolescents [BMI z-score (mean ± SEM) = 0.6 ± 0.09 and 0.8 ± 0.07 in females and males, respectively] and in 51 age-matched obese adolescents [BMI z-score (mean ± SEM) = 2.8 ± 0.12 and 2.9 ± 0.08 in female and males, respectively] by a time-resolved amplified cryptate emission technology assay.

Results

Plasma MR-proADM levels resulted significantly higher in obese than in normal-weight adolescents (MR-proADM: 0.33 ± 0.1 vs 0.40 ± 0.1 nmol/L, p < 0.0001). Using univariate analysis, we observed that MR-proADM correlated significantly with BMI z-score (p < 0.0001), fat mass (p < 0.0001), circulating insulin (p < 0.004), HOMA-IR (p < 0.005), total cholesterol (p < 0.03) and LDL-cholesterol (p < 0.05). Including MR-proADM as response variable and its significant correlates into a multiple regression analysis, we observed that fat mass (p = 0.014) and BMI z-score (p = 0.036) were independent determinants of circulating MR-proADM.

Conclusions

Our study shows for the first time that obese adolescents have higher circulating levels of MR-proADM compared with normal-weight, appropriate controls suggesting its important involvement in obese patients.

Trujillo ME, Scherer PE (2006) Adipose tissue-derived factors: impact on health and disease. Endocr Rev 27:762–778CrossRef

Li Y, Jiang C, Wang X, Zhang Y, Shibahara S, Takahashi K (2007) Adrenomedullin is a novel adipokine: adrenomedullin in adipocytes and adipose tissues. Peptides 28:1129–1143CrossRef

Kitamura K, Kangawa K, Kawamoto M et al (1993) Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma. Biochem Biophys Res Commun 192:553–560CrossRef

Bunton DC, Petrie MC, Hillier C, Johnston F, McMurray JJ (2004) The clinical relevance of adrenomedullin: a promising profile? Pharmacol Ther 103:179–201CrossRef

Ishimitsu T, Nishikimi T, Saito Y et al (1994) Plasma levels of adrenomedullin, a newly identified hypotensive peptide, in patients with hypertension and renal failure. J Clin Invest 94:2158–2161CrossRef

Kobayashi K, Kitamura K, Etoh T et al (1996) Increased plasma adrenomedullin levels in chronic congestive heart failure. Am Heart J 131:994–998CrossRef

Morales MA, Del Ry S, Startari U et al (2006) Plasma adrenomedullin relation with doppler-derived dP/dt in patients with congestive heart failure. Clin Cardiol 29:126–130CrossRef

Morales MA, Maltinti M, Piacenti M, Turchi S, Giannessi D, Del Ry S (2010) Adrenomedullin plasma levels predict left ventricular reverse remodeling after cardiac resynchronization therapy. Pacing Clin Electrophysiol 33:865–872CrossRef

Hirata Y, Mitaka C, Sato K et al (1996) Increased circulating adrenomedullin, a novel vasodilatory peptide, in sepsis. J Clin Endocrinol Metab 81:1449–1453

10.

Minami J, Nishikimi T, Ishimitsu T, Makino Y, Kawano Y, Takishita S et al (2000) Effect of a hypocaloric diet on adrenomedullin and natriuretic peptides in obese patients with essential hypertension. J Cardiovasc Pharmacol 36:S83–S86CrossRef

11.

Kato J, Tsuruda T, Kita T, Kitamura K, Eto T (2005) Adrenomedullin. A protective factor for blood vessels. Arterioscler Thromb Vasc Biol 25:2480–2487CrossRef

12.

Ishimitsu T, Ono H, Minami J, Matsuoka H (2006) Pathophysiologic and therapeutic implications of adrenomedullin in cardiovascular disorders. Pharmacol Ther 111:909–927CrossRef

13.

Kinoshita H, Kato K, Kuroki M et al (2000) Plasma adrenomedullin levels in patients with diabetes. Diabetes Care 23:253–254CrossRef

14.

National Cholesterol Education Program (NCEP) Expert panel on detection, evaluation, and treatment of high blood cholesterol in sdults (adult treatment panel III) (2002) Third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation 106:3143–3421

15.

Guerre-Millo M (2002) Adipose tissue hormones. J Endocrinol Invest 25:855–861CrossRef

16.

Vila G, Riedl M, Maier C et al (2009) Plasma MR-proADM correlates to BMI and decreases in relation to leptin after gastric bypass surgery. Obesity 17:1184–1188

17.

Harmancey R, Senard JM, Rouet P, Pathak A, Smih F (2007) Adrenomedullin inhibits adipogenesis under transcriptional control of insulin. Diabetes 56:553–563CrossRef

18.

Katsuki A, Sumida Y, Gabazza EC et al (2002) Acute hyperinsulinemia is associated with increased circulating levels of adrenomedullin in patients with type 2 diabetes mellitus. Eur J Endocrinol 147:71–75CrossRef

19.

Kohno M, Yokokawa K, Kano H et al (1997) Adrenomedullin is a potent inhibitor of angiotensin II-induced migration of human coronary artery smooth muscle cells. Hypertension 29:1309–1313CrossRef

20.

Sokol RJ (2000) The chronic disease of childhood obesity: the sleeping giant has awakened. J Pediatr 136:711–713CrossRef

21.

Morgenthaler NG, Struck J, Alonso C, Bergmann A (2005) Measurement of midregional proadrenomedullin in plasma with an immunoluminometric assay. Clin Chem 51:1823–1829CrossRef

22.

Struck J, Tao C, Morgenthaler NG, Bergmann A (2004) Identification of an adrenomedullin precursor fragment in plasma of sepsis patients. Peptides 25:1369–1372CrossRef

23.

Cole TJ, Green PJ (1992) Smoothing reference centile curves: the LMS method and penalized likelihood. Stat Med 11:1305–1319CrossRef

24.

Cole TJ, Bellizzi MC, Flegal KM, Diettz WH (2000) Establishing a standard definition for child overweight and obesity worldwide: international survey. BMJ 320:1240–1243CrossRef

25.

McCarthy HD, Cole TJ, Fry T, Jebb SA, Prentice AM (2006) Body fat reference curves for children. Int J Obesity 30:598–602CrossRef

26.

The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents (2004) National High Blood Pressure Education Program Working Group on high blood pressure in children and adolescents. Pediatrics 114:555–576

27.

Mathis G (1993) Rare earth cryptates and homogeneous fluoroimmunoassays with human sera. Clin Chem 39:1953–1959

28.

Del Ry S, Cantinotti M, Cabiati M et al (2012) Plasma C-type natriuretic peptide levels in healthy children. Peptides 33:83–86CrossRef

29.

Prontera C, Emdin M, Zucchelli GC, Ripoli A, Passino A, Clerico A (2003) Automated electrochemiluminescent immunoassay for N-terminal pro-BNP compared with IRMAs for ANP and BNP in heart failure patients and healthy individuals. Clin Chem 49:1552–1554CrossRef

30.

Cantinotti M, Storti S, Parri MS, Prontera C, Murzi B, Clerico A (2010) Reference intervals for brain natriuretic peptide in healthy newborns and infants measured with automated immunoassay platform. Clin Chem Lab Med 48:697–700

31.

Nir A, Lindinger A, Rauh M et al (2009) NT-pro-B-type natriuretic peptide in infants and children: reference values based on combined data from four studies. Pediatr Cardiol 30:3–8CrossRef

32.

Kato J, Kitamura K, Uemura T et al (2002) Plasma levels of adenomedullin and atrial and brain natriuretic peptides in the general population: their relations to age and pulse pressure. Hypertens Res 25:887–889CrossRef

33.

Collinson PO, Gaze DC (2007) Biomarkers of cardiovascular damage. Med Princ Pract 16:247–261CrossRef

34.

Hotamisligil GS (2006) Inflammation and metabolic disorders. Nature 444:860–867CrossRef

35.

Ye J, Gao Z, Yin J, He Q (2007) Hypoxia is a potential risk factor for chronic inflammation and adiponectin reduction in adipose tissue of ob/ob and dietary obese mice. Am J Physiol Endocrinol Metab 293:E1118–E1128CrossRef

36.

Allen MA, Smith PM, Ferguson AV (1997) Adrenomedullin microinjection into the area postrema increases blood pressure. Am J Physiol 272:R1698–R1703

37.

Takahashi H, Watanabe TX, Nishimura M et al (1994) Centrally induced vasopressor and sympathetic responses to a novel endogenous peptide, adrenomedullin, in anesthetized rats. Am J Hypertens 7:478–482

38.

Martinez A, Weaver C, Lopez J et al (1996) Regulation of insulin secretion and blood glucose metabolism by adrenomedullin. Endocrinology 137:2626–2632

39.

Satoh F, Takahashi K, Murakami O et al (1996) Immunocytochemical localization of adrenomedullin-like immunoreactivity in the human hypothalamus and the adrenal gland. Neurosci Lett 203:207–210CrossRef

Titel: Mid-regional-pro-adrenomedullin plasma levels are increased in obese adolescents
verfasst von: Silvia Del Ry
Manuela Cabiati
Vanessa Bianchi
Laura Caponi
Pietro Di Cecco
Benedetta Marchi
Emioli Randazzo
Chiara Caselli
Tommaso Prescimone
Aldo Clerico
Giovanni Federico
Publikationsdatum: 29.05.2015
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nutrition / Ausgabe 3/2016
Print ISSN: 1436-6207
Elektronische ISSN: 1436-6215
DOI: https://doi.org/10.1007/s00394-015-0938-6

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Mid-regional-pro-adrenomedullin plasma levels are increased in obese adolescents

Abstract

Purpose

Methods

Results

Conclusions

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Viel Bewegung in der Parkinsonforschung

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Innere Medizin

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2016

Does a diet low in FODMAPs reduce symptoms associated with functional gastrointestinal disorders? A comprehensive systematic review and meta-analysis

Moderate physical training attenuates perinatal low-protein-induced spleen lymphocyte apoptosis in endotoxemic adult offspring rats

Vinegar decreases blood pressure by down-regulating AT1R expression via the AMPK/PGC-1α/PPARγ pathway in spontaneously hypertensive rats

Association between n-3 polyunsaturated fatty acids in erythrocytes and metabolic syndrome in Chinese men and women

Medium-chain triglyceride ameliorates insulin resistance and inflammation in high fat diet-induced obese mice

Examination of iodine status in the German population: an example for methodological pitfalls of the current approach of iodine status assessment

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Viel Bewegung in der Parkinsonforschung

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Innere Medizin